We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+0.33%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$80.3M
AUM Growth
-$83.2M
Cap. Flow
-$80.2M
Cap. Flow %
-99.96%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
CERO
CERo Therapeutics
CERO
+$8.08M
2
QTTB icon
Q32 Bio
QTTB
+$4.42M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$92.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
1
DELISTED
Verve Therapeutics
VERV
$26.7M 33.23%
2,008,809
– –
ERAS icon
2
Erasca
ERAS
$6.68B
$22.8M 28.37%
11,055,554
– –
GOSS icon
3
Gossamer Bio
GOSS
$68.5M
$9.51M 11.84%
8,055,916
– –
DNLI icon
4
Denali Therapeutics
DNLI
$3.68B
$7.82M 9.75%
381,249
– –
QTTB icon
5
Q32 Bio
QTTB
$456M
$5.46M 6.8%
+320,482
New +$4.42M
CERO
6
DELISTED
CERo Therapeutics
CERO
$4.43M 5.52%
+722
New +$8.08M
OMIC
7
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.95M 2.43%
126,631
– –
UBX
8
DELISTED
Unity Biotechnology
UBX
$1.65M 2.05%
1,004,817
– –
RVMD icon
9
Revolution Medicines
RVMD
$40.1B
– –
-3,233,490
Closed -$92.7M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q1 2024 Portfolio in Review

As of Q1 2024, Arch Venture Management held 9 positions worth $80.3M, down 51% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $80.2M in Q1 2024, closing 1 position. Its most notable exit was Revolution Medicines, an estimated $92.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Arch Venture Management opened a new position in CERo Therapeutics worth $4.43M.

  • Arch Venture Management's largest Q1 2024 buy was CERo Therapeutics: 722 shares worth $4.43M.
  • Arch Venture Management fully exited Revolution Medicines in Q1 2024, selling an estimated $92.7M.
  • Arch Venture Management's ten largest holdings make up 100% of its $80.3M portfolio in Q1 2024.
  • Arch Venture Management opened 2 new positions and closed 1 in Q1 2024.
  • Arch Venture Management's portfolio value fell 51% quarter-over-quarter to $80.3M.

Based on Arch Venture Management's 13F filing for Q1 2024, filed 15 May 2024.